A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
about
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular diseaseTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesMomelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisThe development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
P2860
Q26750725-ACFB1695-1DAB-48E4-8729-28B3CBBD0CB4Q26752940-E13AB693-379F-4DBB-9399-DE7B0875EB6AQ30244032-BD45F43B-6819-411E-81AC-24C583CF04ACQ33433006-BC04C7E4-DF41-420D-AE35-DCD8C3411DB9Q33434284-4A5F7D39-3C37-4FF5-A2CE-8925979E172EQ33435178-6B12238E-2180-4D92-84BC-1A2FE7CE0632Q38613880-CF874C0E-39A1-4EAF-B900-BE1745BE435EQ38815464-58C96ED0-F1F5-47EF-ADF1-B4F6C79611F6Q48109284-D71FB311-5F25-4BCD-B5EC-4AB84D2B20C1Q50440650-07E171C1-C735-47E7-8F69-B0811A461FF7
P2860
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@ast
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@en
type
label
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@ast
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@en
prefLabel
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@ast
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@en
P2093
P2860
P356
P1433
P1476
A phase 2 randomized dose-rang ...... in patients with myelofibrosis
@en
P2093
A Pardanani
C Jamieson
C Lebedinsky
N Y Gabrail
P2860
P2888
P356
10.1038/BCJ.2015.63
P577
2015-08-07T00:00:00Z